Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).
Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.
Dr. Marks investigates the molecular mechanisms underlying the formation of cell type-specific lysosome-related organelles; the assembly, delivery and function of their contents; and how these processes are impacted by genetic diseases.
Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.
Dr. Roizen's research program aims to understand non-calciometabolic effects of vitamin D and to use this understanding to design new therapeutic approaches to common diseases such as sarcopenia and obesity.
Dr. Hartung is the interim director of CHOP's Sickle Cell Center and the director of innovation of the CuRED Frontier Program. His clinical focus is on bone marrow failure syndromes and sickle cell disease and his research focus is on entrepreneurial science and medical device development.
Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.
Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.
Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.
Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.